This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.

The original disclosure in Japanese was released on Oct. 25, 2022

Takara Holdings Inc.

 

Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2023

Kyoto, Japan—Takara Holdings announced revisions to the business results forecast for the first half of the fiscal year ending March 31, 20223(from April 1, 2022, to March 31, 2023) that it released on August 4, 2022, as stated below. These revisions were based on consideration of recent performance trends.
 

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2023 (from April 1, 2022, to September 30, 2022)

(Millions of yen / %)

 

2. Reason for revision

For the first half of the fiscal year ending March 31, 2023, net sales of Takara Shuzo and the Takara Shuzo International Group are expected to be roughly the same level as the previous forecast (announced on August 4, 2022). Meanwhile, net sales are expected to exceed the previous forecast for the Takara Bio Group, with the seventh wave of COVID-19 having driven the sales of relevant testing products to outperform the forecast.

 

In terms of profit, Takara Shuzo expects operating income to increase contrary to the previous forecast mainly due to decreases in costs, and the Takara Shuzo International Group expects operating income to be roughly in line with the forecast. The Takara Bio Group is expected to report an operating income higher than the forecast, due to an increase in gross profit following the increase in net sales.

 

As a result, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast for the Takara Group as a whole.

 

Further, today consolidated subsidiary Takara Bio Inc. (Tokyo Stock Exchange Prime Market, security code number: 4974) also announced revisions to forecasts for the six-month period ended September 30, 2022.
 

 


3. Full-year business results forecast for the fiscal year ending March 31, 2023


The Company is currently evaluating whether or not revisions to forecasts for consolidated business results for the full fiscal year are necessary and considering the details of possible revisions. The Company will make an announcement in this regard when it announces its business results for the first half on November 10, 2023.
 

*The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 10, 2022.